AbCellera Biologics(ABCL) - 2021 Q3 - Earnings Call Presentation

Business Highlights - AbCellera has reached a cumulative total of 155 programs under contract[9, 11] - The company has $754 million in cash, cash equivalents, and marketable securities[9] - Accounts and accrued receivable amount to $44 million[9] - One molecule has entered clinical testing[9] Strategic Expansion - AbCellera is expanding capabilities against difficult-to-drug targets through the acquisition of TetraGenetics[19] - The company's OrthoMab™ bispecific engineering platform provides partners with solutions for generating bispecific antibodies[21, 22] Financial Performance - Q3 2021 revenue reflects robust discovery partnership activity, totaling $5.5 million[40] - The company experienced a net loss of $21.4 million, equivalent to ($0.08) per share[47] Pipeline Development - AbCellera has five molecules in the clinic and over a dozen in preclinical development[38] - One program, IVX-01, developed in partnership, has advanced into clinical field study for animal health[27, 39] Partnership Growth - The company's partnership business is on track for its strongest year, with 35 discovery partners[35] - There are 69 cumulative program starts[35]